

International Prostate Cancer Symposium  
Where translational research meets therapeutic innovation

# IPCS 2026

## Detailed Programme

28-29 April 2026  
Palazzo dei Congressi, Lugano, Switzerland

 [www.apccc.org/ipcs](http://www.apccc.org/ipcs)

IPCS 2026 is organised by the  
Foundation for the Institute of  
Oncology Research (IOR) in  
collaboration with APC Society,  
with the support of

**AAGR** American Association  
for Cancer Research®  
FINDING CURES TOGETHER™

**EAU** European  
Association  
of Urology

# Tuesday April 28



14:00 – 14:10

## WELCOME and OPENING REMARKS

Chairs **A. Alimonti**, **J.P. Theurillat** and **S. Gillessen**  
Institute of Oncology Research, CH

---

14:10 – 14:50

## AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) OPENING LECTURE

E-Chaired by **M. Foti**, CEO of the American Association for Cancer Research

*Targeting AR: Opportunities and Drawbacks*



**C. Sawyers**

Chair of the human oncology and pathogenesis program,  
Memorial Sloan Kettering Cancer Center, USA

---

SESSION 1

## NEXT-GENERATION AR INHIBITORS: DEGRADERS & BEYOND

Chaired by **J.P. Theurillat**, Institute of Oncology Research, CH  
**A.J. Armstrong**, Duke University School of Medicine, USA

---

14:50 – 15:10

*Targeted protein degradation for regulation of nuclear hormone receptors*



**N.H. Thomä**

EPFL, CH

---

15:10 – 15:30

*Preventing Disease Progression under AR suppression Through TRIM24 Degradation*



**J.P. Theurillat**

Institute of Oncology Research (IOR), CH

---

15:30 – 15:50

*2 Selected Abstract Oral Presentations*

*Targeting lineage plasticity for castration-resistant prostate cancer by inhibiting a novel metabolic vulnerability.*

**H.-K. Lin**

*Targeting of FOXA1 and FOXA2 by Small Molecules Disables the Oncogenic Output of Castration Resistant Prostate Cancer.*

**N. Formaggio**

---

15:50 - 16:10

## EUROPEAN ASSOCIATION OF UROLOGY (EAU) LECTURE

Chaired by **J. Walz**, Institut Paoli-Calmettes Cancer Centre, FR

*Neoadjuvant therapy in prostate cancer: present and future directions*



**A. Briganti**

Vita-Salute San Raffaele University, IT

16:10 - 16:40

## Coffee break

16:40 - 17:00

*Lessons from clinical trials involving AR degraders*



**A.J. Armstrong**

Duke University School of Medicine, USA

## SESSION 2

## COMBINATION THERAPIES: HOW TO PREVENT ARPi RESISTANCE

Chaired by **M. Rubin**, University of Bern, CH

**A. Briganti**, Vita-Salute San Raffaele University, IT

**J. Walz**, Institut Paoli-Calmettes Cancer Centre, FR

17:00 - 17:20

*Targeting heterogeneity in metastatic prostate cancer to prevent resistance*



**P.S. Nelson**

Vice President of Precision Oncology Fred Hutch,  
Fred Hutchinson Cancer Center, USA

17:20 - 17:40

*Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance*




**W. Zwart**

Chair of the NKI Translational Research Board,  
Netherlands Cancer Institute, NL

17:40 - 18:00

*A Unifying Genetic Hallmark of Lethal Metastatic Prostate Cancer*



**L. Trotman**

Cancer Center Cold Spring Harbor Laboratory, USA

18:00 - 18:20

*2 Selected Abstract Oral Presentations*

*11-oxygenated androgens sustain Androgen Receptor activation and drive advanced prostate cancer progression.*

**A. Lacoste**

*Evolutionary Trajectories Driving Lethal Prostate Cancer.*

**O. Vainauskas**

# Wednesday April 29



09:00 – 09:30

## KEYNOTE LECTURE

Chaired by **H. Beltran**, Dana-Farber Cancer Institute, USA  
*Liquid Biopsies: Methods and Applications*



**F. Demichelis**

Vice-Rector for research of the University of Trento, IT

SESSION 3

## PREDICTIVE BIOMARKERS: CAN WE DISCERN SIGNAL FROM NOISE?

Chaired by **H. Beltran**, Dana-Farber Cancer Institute, USA  
**A. Bjartell**, Lund University, SE

09:30 – 09:50

*Detection of Neuroendocrine Prostate Cancer via DNA Methylation*



**H. Beltran**

Dana-Farber Cancer Institute, USA

09:50 – 10:10

*Molecular sub-grouping of metastatic hormone-sensitive prostate cancer*



**G. Attard**

University College London, UK

10:10 – 10:30

## Coffee break

10:30 – 10:50

*Predictive markers for metastatic hormone-sensitive prostate cancer*



**C. Sweeney**

Director of the South Australian Immunogenomics Cancer Institute, University of Adelaide, AU

10:50 – 11:20

## 3 Selected Abstract Oral Presentations

*Combined circulating tumor DNA and serum prostate specific antigen for dynamic monitoring of metastatic prostate cancer starting first-line treatment.*

**A. Jayaram**

*PLA Hyperplex Proteomic Profiling in mCRPC Serial Plasma Samples in the TO-PARP trial*

**T. Taha**

*Clinical and Functional Genomic Drivers of ARPI Resistance: Creating a Learning Loop From Retrospective Insights to Prospective Clinical Trial Strategy.*

**K. Shah**

## SESSION 4

### NEW FRONTIERS IN IMMUNOTHERAPY PROSTATE CANCER?

Chaired by **J. de Bono**, The Institute of Cancer Research, UK  
**C. Drake**, VP Immuno-Oncology, Janssen, USA

11:20 – 11:40

*Immune response patterns in prostate cancer*



**A. Alimonti**

Director of the Institute of Oncology Research (IOR), CH

11:40 – 12:00

*Novel T-cells engagers in prostate cancer*



**J. de Bono**

Director of the Drug Development Unit, The Institute of Cancer Research, UK

12:00– 12:20

*Next-generation approaches to immunotherapy*



**C. Drake**

Adjunct Professor of Medicine and Urology, Columbia University Herbert Irving Comprehensive Cancer Center, USA

12:20 – 12:30

*1 Selected Abstract Oral Presentation*

*TET2-CHIP Remodels the Myeloid Tumor Microenvironment and Accelerates Castration-Resistant Prostate Cancer*

**M. Maddalena**

12:30– 14:00

**Lunch break - Convention Centre Main Hall and POSTER SESSION - Room B2**

The Poster Session will be held during the break

14:00 - 14:30

**POSTER FLASH - Room B1**

Chaired by **J.P. Theurillat**, Institute of Oncology Research, CH

**15 Selected Abstracts Oral Presentations 2 min**

*Elucidating the role of DNA-dependent dimerization for androgen receptor signaling.*

**K. Peperstraete**

*Epithelial cell-intrinsic role of SOCS1 in maintaining prostate tissue homeostasis, attenuating inflammation and reducing susceptibility to carcinogenesis.*

**S. Ilangumaran**

*Decoding the Complexity of Prostate Cancer Evolution: Uncovering Heterogeneous Cell States by Cutting-Edge Integrative Approaches.*

**G. A. Cassanmagnago**

*From Reconstruction to Resolution: Platform Approaches to Engineer the Prostate Cancer Phenoscape and Map Its Evolution.*

**M. Bezzi**

*Chronic Circadian Disruption Promotes Neuroendocrine Prostate Cancer Pathogenesis.*

**W. Huang**

14:00 - 14:30

## cont. POSTER FLASH - Room B1

15 Selected Abstracts Oral Presentations 2 min

*Prostate cancer-derived extracellular vesicles promote GDF15<sup>+</sup> immunoregulatory macrophage polarization within the tumor microenvironment.*

**A. Mazumdar**

*Drosophila accessory gland: a tool to unveil and understand the molecular program of resistance.*

**C. de Jossineau**

*Immuno-metabolic phenotypes in metastatic hormone-sensitive prostate cancer (mHSPC): post-hoc analysis of the ENZAMET trial (ANZUP 1304).*

**L. Horvath**

*Non-invasive prostate cancer subtyping using 5hmC-sequencing of cellfree DNA.*

**M. Sjöström**

*High-throughput circulating proteome for non-invasive identification of clinically significant prostate cancer.*

**P. Ostano**

*Building Movember-SAiGENCI-Transformational Integrated Repositor (MSTIR): A global database to enable clinical and biomarker discovery in prostate cancer care.*

**S. McKeown**

*Intracellular osteopontin dictates the release of TNF $\alpha$  by mast cells to restrain neuroendocrine prostate cancer.*

**E. Jachetti**

*Novel patient-derived organoid xenograft models reveal molecular and clinical trajectories of prostate cancer progression.*

**R. Parmentier**

*Restoring the PTEN Tumor Suppressor Axis: Small-Molecule Inhibition of the WWP1/WWP2 E3 Ligases.*

**J. Sgrignani**

*Biological determinants of prostate cancer response to neoadjuvant hormone therapy.*

**M. Ismail**

14:40 - 15:00

## KEYNOTE LECTURE

Chaired by **L. Emmett**, St Vincent's Hospital Sydney, AU  
*Radioligand Therapies: How to improve outcomes?*



**M. Hofman**

Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, AU

SESSION 5

## THERANOSTICS FOR TARGETED THERAPY IN PROSTATE CANCER

Chaired by **M. Hofman**, Peter MacCallum Cancer Centre, AU  
**L. Emmett**, St Vincent's Hospital Sydney, AU

15:00 - 15:20

*Next-Generation Radiopharmaceuticals: What's on the Horizon?*



**K. Herrmann**

Chair of the Department of Nuclear Medicine, University Hospital Essen, DE

# Wednesday, April 29

15:20 - 15:40

*Lu-PSMA to treat metastatic castration-resistance prostate cancer*



**L. Emmett**

Director of Theranostics and Nuclear medicine,  
St Vincent's Hospital Sydney, AU

---

15:40 - 16:00

*2 Selected Abstract Oral Presentations*

*Dose Optimisation and PSMA Receptor intensification with <sup>177</sup>Lu-PSMA Therapy in metastatic castration-resistant prostate cancer (mCRPC): The Randomised Phase 2 OPTIMAL-PSM.*

**L. Emmett**

*ProstACT Global: A phase 3 study of <sup>177</sup>Lu-rosopitamab tetraxetan plus standard of care vs standard of care alone in patients with mCRPC.*

**D. Castellano**

---

16:00 - 16:20

**Coffee break**

---

**SESSION 6**

## **EMERGING ANTIBODY-DRUG CONJUGATES**

Chaired by **T. Powles**, University of London, UK

**E. Antonarakis**, University of Minnesota, USA

---

16:20 - 16:40

*B7-H3 as an actionable therapeutic target*



**E. Antonarakis**

Associate Director in Translation Research Masonic Cancer Center, University of Minnesota, USA

---

16:40 - 17:00

*Innovative payloads for ADCs in cancer treatment*



**T. Powles**

Director of Barts Cancer Centre, University of London, UK

---

17:00 - 17:10

*1 Selected Abstract Oral Presentation*

*TD001, a PSMA-targeting ADC, exhibits potent antitumor activity and optimal pharmacological properties in castration-resistant prostate cancer models.*

**D. Impellizzeri**

---

17:10 - 17:25

## **CLOSING REMARKS**

Chairs **A. Alimonti**, **J.P. Theurillat** and **S. Gillessen**

Institute of Oncology Research, CH

---